Multi-sequential surface plasmon resonance analysis of haptoglobin-lectin complex in sera of patients with malignant and benign prostate diseases

Analytical Biochemistry

Volumn 419, Issue 2, 2011, Pages 241-249

  Kazuno, Saiko ^a   Fujimura, Tsutomu ^a   Arai, Takahiro ^a   Ueno, Takashi ^a,b   Nagao, Keiji ^a   Fujime, Makoto ^a   Murayama, Kimie ^a  

^a JUNTENDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b JUNTENDO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Acute phase protein; Glycosylation; Haptoglobin; Lectin; SNA 1; SPR

Indexed keywords

DIAGNOSIS; DISEASES; GLYCOPROTEINS; GLYCOSYLATION; PLASMONS; PROTEINS; UROLOGY;

ACUTE PHASE PROTEINS; BENIGN PROSTATIC HYPERTROPHY; CANCER DIAGNOSTICS; HAPTOGLOBIN; LECTIN; PROSTATE CANCERS; SEQUENTIAL ANALYSIS; SNA-1;

SURFACE PLASMON RESONANCE;

AAA PROTEIN; ALL PROTEIN; GLYCOPROTEIN; HAPTOGLOBIN; LECTIN; MAA PROTEIN; MULTIPROTEIN COMPLEX; PHA L 4 PROTEIN; PLANT LECTIN; SUGAR; UNCLASSIFIED DRUG; VEGETABLE PROTEIN;

ALEURIA AURANTIA; ARTICLE; CANCER SCREENING; CLINICAL ARTICLE; CONTROLLED STUDY; DILUTION; GLEASON SCORE; GLYCOSYLATION; HUMAN; HUMAN TISSUE; MALE; MEDICINAL PLANT; MICROANALYSIS; MULTISEQUENTIAL SURFACE PLASMON RESONANCE; PHASEOLUS VULGARIS; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; PROSTATE HYPERTROPHY; PROSTATE TUMOR; PROTEIN ANALYSIS; PROTEIN BINDING; PROTEIN BLOOD LEVEL; SAMBUCUS NIGRA; SURFACE PLASMON RESONANCE;

EID: 80054078249     PISSN: 00032697     EISSN: 10960309     Source Type: Journal    
DOI: 10.1016/j.ab.2011.08.029     Document Type: Article

References (40)

1. S. Srivastava, and R.-G. Srivastava Proteomics in the forefront of cancer biomarker discovery J. Proteome Res. 4 2005 1098 1103
2. B. Ye, D.W. Cramer, S.J. Skates, S.P. Gygi, V. Pratomo, L. Fu, N.K. Horick, L.J. Licklider, J.O. Schorge, R.S. Berkowitz, and S.C. Mok Haptoglobin-α subunit as potential serum biomarker in ovarian cancer: identification and characterization using proteomic profiling and mass spectrometry Clin. Cancer Res. 9 2003 2904 2911
3. R.G. Uzzo, W.H. Pinover, E.M. Horwitz, A. Parlanti, S. Mazzoni, S. Raysor, I. Mirchandani, R.E. Greenberg, A. Pollack, G.E. Hanks, and D. Watkins-Bruner Free prostate-specific antigen improves prostate cancer detection in a high-risk population of men with a normal total PSA and digital rectal examination Urology 61 2003 754 759
4. A.E. Pelzer, J. Bektic, T. Akkad, S. Ongarello, G. Schaefer, C. Schwentner, F. Frauscher, G. Bartsch, and W. Horninger Under diagnosis and over diagnosis of prostate cancer in a screening population with serum PSA 2 to 10 ng/ml J. Urol. 178 2007 93 97
5. J.S. Krumholtz, G.F. Carvalhal, C.G. Ramos, D.S. Smith, P. Thorson, Y. Yan, P.A. Humphrey, K.A. Roehl, and W.J. Catalona Prostate-specific antigen cutoff of 2.6 ng/ml for prostate cancer screening is associated with favorable pathologic tumor features Urology 60 2002 469 474
6. E.S. Leman, G.W. Cannon, B.J. Trock, L.J. Sokoll, D.W. Chan, L. Mangold, A.W. Partin, and R.H. Getzenberg EPCA-2: a highly specific serum marker for prostate cancer Urology 69 2007 714 720
7. A. Jemal, R. Siegel, E. Ward, Y. Hao, J. Xu, T. Murray, and M.J. Thun Cancer statistics, 2008 CA Cancer J. Clin. 58 2008 71 96
8. O. Ishizuka, Y. Mimura, T. Oguchi, M. Kawakami, and O. Nishizawa Importance of transition zone prostate biopsies in patients with gray-zone PSA levels undergoing the ultrasound-guided systematic ten-biopsy regimen for the first time Urol. Int. 74 2005 23 26
9. S. Yamamoto, T. Maruyama, N. Kondoh, M. Nojima, H. Takiuchi, S. Hirota, and H. Shima Diagnostic efficacy of free to total ratio of prostate-specific antigen and prostate-specific antigen velocity, singly and in combination, in detecting prostate cancer in patients with total serum prostate-specific antigen between 4 and 10 ng/ml Int. Urol. Nephrol. 40 2008 85 89
10. X. Filella, D. Truan, J. Alcover, R. Gutierrez, R. Molina, F. Coca, and A.M. Ballesta Complexed prostate-specific antigen for the detection of prostate cancer Anticancer Res. 24 2004 4181 4185
11. L.F. Chu, Z. Chen, and T.A. Stamey Different molecular forms of uncomplexed prostate specific antigen (PSA) show similar immunoreactivities J. Urol. 161 1999 2009 2012
12. Y. Nakano, K. Okamura, S. Takamura, N. Okamoto, M. Narishima, Y. Yoshino, R. Hattori, Y. Ono, S. Ohshima, and T. Nagasaka Measurement of prostate specific antigen complexed to α1-antichymotrypsin to avoid unnecessary biopsy in patients with serum prostate specific antigen levels 4-20 ng/ml Int. J. Urol. 12 2005 721 727
13. M.P.A. Ebert, M. Korc, P. Malfertheiner, and C. Röcken Advances, challenges, and limitations in serum-proteome-based cancer diagnosis J. Proteome Res. 5 2006 19 25
14. Y. Chen, B.K. Lim, S.C. Peh, P.S. Abdul-Rahman, and O.H. Hashim Profiling of serum and tissue high abundance acute-phase proteins of patients with epithelial and germ line ovarian carcinoma Proteome Sci. 6 2008 20 30
15. S.M. Zhang, J. Lin, N.R. Cook, I.M. Lee, J.E. Manson, J.E. Buring, and P.M. Ridker C-reactive protein and risk of breast cancer J. Natl Cancer Inst. 99 2007 890 894
16. I.L. Ang, T.C. Poon, P.B. Lai, A.T. Chan, S.M. Ngai, A.Y. Hui, P.J. Johnson, and J.J. Sung Study of serum haptoglobin and its glycoforms in the diagnosis of hepatocellular carcinoma: a glycoproteomic approach J. Proteome Res. 5 2006 2691 2700
17. C.M. Maciel, M. Junqueira, M.E. Paschoal, M.T. Kawamura, R.L. Duarte, G. Carvalho Mda, and G.B. Domont Differential proteomic serum pattern of low molecular weight proteins expressed by adenocarcinoma lung cancer patients J. Exp. Ther. Oncol. 5 2005 31 38
18. N. Ahmed, K.T. Oliva, G. Barker, P. Hoffmann, S. Reeve, I.A. Smith, M.A. Quinn, and G.E. Rice Proteomic tracking of serum protein isoforms as screening biomarkers of ovarian cancer Proteomics 5 2005 4625 4636
19. K.H. Yu, A.K. Rustgi, and I.A. Blair Characterization of proteins in human pancreatic cancer serum using differential gel electrophoresis and tandem mass spectrometry J. Proteome Res. 4 2005 1742 1751
20. P.X. Xing, G. Young, and I.F. McKenzie Development of a fecal occult blood test using a monoclonal antibody to haptoglobin Redox Rep. 6 2001 363 365
21. B. Hamrita, K. Chahed, M. Trimeche, C.L. Guillier, P. Hammann, A. Chaieb, S. Korbi, and L. Chouchane Proteomics-based identification of alpha1-antitrypsin and haptoglobin precursors as novel serum markers in infiltrating ductal breast carcinomas Clin. Chim. Acta 404 2009 111 118
22. R. Saldova, M.R. Wormald, R.A. Dwek, and P.M. Rudd Glycosylation changes on serum glycoproteins in ovarian cancer may contribute to disease pathogenesis Dis. Markers 25 2008 219 232
23. N. Okuyama, Y. Ide, M. Nakano, T. Nakagawa, K. Yamanaka, K. Moriwaki, K. Murata, H. Ohigashi, S. Yokoyama, H. Eguchi, O. Ishikawa, T. Ito, M. Kato, A. Kasahara, S. Kawano, J. Gu, N. Taniguchi, and E. Miyoshi Fucosylated haptoglobin is a novel marker for pancreatic cancer: a detailed analysis of the oligosaccharide structure and a possible mechanism for fucosylation Int. J. Cancer 118 2006 2803 2808
24. T. Kudo, H. Nakagawa, M. Takahashi, J. Hamaguchi, N. Kamiyama, H. Yokoo, K. Nakanishi, T. Nakagawa, T. Kamiyama, K. Deguchi, S. Nishimura, and S. Todo N-Glycan alterations are associated with drug resistance in human hepatocellular carcinoma Mol. Cancer 6 2007 32 40
25. M. Nakano, T. Nakagawa, T. Ito, T. Kitada, T. Hijioka, A. Kasahara, M. Tajiri, Y. Wada, N. Taniguchi, and E. Miyoshi Site-specific analysis of N-glycans on haptoglobin in sera of patients with pancreatic cancer: a novel approach for the development of tumor markers Int. J. Cancer 122 2008 2301 2309
26. 4) as a new marker for prostate cancer Int. J. Cancer 115 2005 105 113
27. T. Fujimura, Y. Shinohara, B. Tissot, P.-C. Pang, M. Kurogochi, S. Saito, Y. Arai, M. Sadilek, K. Murayama, A. Dell, S. Nishimura, and S. Hakomori Glycosylation status of haptoglobin in sera of patients with prostate cancer vs. benign prostate disease or normal subjects Int. J. Cancer 122 2008 39 49
28. S. Saito, Y. Murayama, Y. Pan, T. Taima, T. Fujimura, K. Murayama, M. Sadilek, S. Egawa, S. Ueno, A. Ito, S. Ishidoya, H. Nakagawa, M. Kato, M. Satoh, M. Endoh, and Y. Arai Haptoglobin-β chain defined by monoclonal antibody RM2 as a novel serum marker for prostate cancer Int. J. Cancer 123 2008 633 640
29. A.W. Partin, M.K. Brawer, G. Bartsch, W. Horninger, S.S. Taneja, H. Lepor, R. Babaian, S.J. Childs, T. Stamey, H.A. Fritsche, L. Sokoll, D.W. Chan, R.P. Thiel, and C.D. Cheli Complexed prostate specific antigen improves specificity for prostate cancer detection: results of a prospective multicenter clinical trial J. Urol. 170 2003 1787 1791
30. J.R. Delanghe, and M.L. De Buyzere Development of an ELISA for the determination of the major haptoglobin phenotype: an interesting technical development and its potential consequences Clin. Chem. 50 2004 1972 1973
31. L. Huang, G. Reekmans, D. Saerens, J.M. Friedt, F. Frederix, L. Francis, S. Muyldermans, A. Campitelli, and C. Van Hoof Prostate-specific antigen immunosensing based on mixed self-assembled monolayers, camel antibodies and colloidal gold enhanced sandwich assays Biosens. Bioelectron. 21 2005 483 490
32. F. Su, C. Xu, M. Taya, K. Murayama, Y. Shinohara, and S. Nishimura Detection of carcinoembryonic antigens using a surface plasmon resonance biosensor Sensors 8 2008 4282 4295
33. B.N. Murthy, S. Sinha, A. Surolia, S.S. Indi, and N. Jayaraman SPR and ITC determination of the kinetics and the thermodynamics of bivalent versus monovalent sugar-ligand-lectin interactions Glycoconj. J. 25 2008 313 321
34. E.M. Munoz, J. Correa, E. Fernandez-Megia, and R. Riguera Probing the relevance of lectin clustering for the reliable evaluation of multivalent carbohydrate recognition J. Am. Chem. Soc. 131 2009 17765 17767
35. J.P. Kim, B.Y. Lee, J. Lee, S. Hong, and S.J. Sim Enhancement of sensitivity and specificity by surface modification of carbon nanotubes in diagnosis of prostate cancer based on carbon nanotube field effect transistors Biosens. Bioelectron. 24 2009 3372 3378
36. H. Vaisocherova, V.M. Faca, A.D. Taylor, S. Hansh, and S. Jiang Comparative study of SPR and ELISA methods based on analysis of CD166/ALCAM levels in cancer and control human sera Biosens. Bioelectron. 24 2009 2143 2148
37. C. Cao, J.P. Kim, B.W. Kim, H. Chae, H.C. Yoon, S.S. Yang, and S.J. Sim A strategy for sensitivity and specificity enhancements in prostate specific antigen-α1-antichymotrypsin detection based on surface plasmon resonance Biosens. Bioelectron. 21 2006 2106 2113
38. J.A. Lofgren, S. Dhandapani, J.J. Pennucci, C.M. Abbott, D.T. Mytych, A. Kaliyaperumal, S.J. Swanson, and M.C. Mullenix Comparing ELISA and surface plasmon resonance for assessing clinical immunogenicity of panitumumab J. Immunol. 178 2007 7467 7472
39. J. Homola Surface plasmon resonance based sensors Springer Ser. Chem. Sens. Biosens. 4 2006
40. H. Vaisocherová, K. Mrkvová, M. Piliarik, P. Jinoch, M. Steinbachová, and J. Homola Surface plasmon resonance biosensor for direct detection of antibody against Epstein-Barr virus Biosens. Bioelectron. 22 2007 1020 1026